$30.67
—
AUM
$1.24B
NAV
—
Expense Ratio
—
Yield
0.00%
52W High
$34.39
52W Low
$20.46
The ARK Genomic Revolution ETF's ("Fund") investment objective is long -term growth of capital.
Top Holdings (35)
| # | Holding | Ticker | Weight |
|---|---|---|---|
| 1 | Tempus AI Inc | — | 8.2504% |
| 2 | CRISPR Therapeutics AG | — | 7.9864% |
| 3 | Twist Bioscience Corp | — | 7.1932% |
| 4 | Personalis Inc | — | 6.1319% |
| 5 | Guardant Health Inc | — | 5.9805% |
| 6 | 10X Genomics Inc | — | 5.2191% |
| 7 | Beam Therapeutics Inc | — | 4.7949% |
| 8 | Illumina Inc | — | 4.5226% |
| 9 | Natera Inc | — | 4.2951% |
| 10 | Recursion Pharmaceuticals Inc | — | 4.0010% |
| 11 | CareDx Inc | — | 3.4340% |
| 12 | Veracyte Inc | — | 3.2834% |
| 13 | Adaptive Biotechnologies Corp | — | 3.1241% |
| 14 | Intellia Therapeutics Inc | — | 3.0946% |
| 15 | Absci Corp | — | 2.8238% |
| 16 | Ionis Pharmaceuticals Inc | — | 2.6122% |
| 17 | Schrodinger Inc/United States | — | 2.3254% |
| 18 | Nurix Therapeutics Inc | — | 2.0666% |
| 19 | Pacific Biosciences of California Inc | — | 1.9782% |
| 20 | Butterfly Network Inc | — | 1.9382% |
| 21 | GeneDx Holdings Corp | — | 1.5559% |
| 22 | Arcturus Therapeutics Holdings Inc | — | 1.5341% |
| 23 | Prime Medicine Inc | — | 1.4924% |
| 24 | Cerus Corp | — | 1.2250% |
| 25 | Amgen Inc | — | 1.2103% |
| 26 | Compass Pathways Plc | — | 1.1275% |
| 27 | Incyte Corp | — | 1.0693% |
| 28 | 908 Devices Inc | — | 0.9798% |
| 29 | AtaiBeckley Inc | — | 0.9748% |
| 30 | Vertex Pharmaceuticals Inc | — | 0.9580% |
| 31 | Caris Life Sciences Inc | — | 0.7412% |
| 32 | Veeva Systems Inc | — | 0.6561% |
| 33 | Quantum-Si Inc | — | 0.6226% |
| 34 | Standard BioTools Inc | — | 0.3370% |
| 35 | Goldman Sachs Financial Square Treasury Obligations Fund | — | 0.2102% |
Last synced May 26, 2026, 5:18 PM · Price and AUM from Yahoo Finance · Holdings from SEC N-PORT filings